Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.

Nardinelli L, Sanabani SS, Didone A, Ferreira Pde B, Serpa M, Novaes MM, Marchiani M, Ruiz AL, Lima IS, Chamone Dde A, Bendit I.

Acta Haematol. 2012;127(4):228-34. doi: 10.1159/000336610. Epub 2012 Apr 13.

PMID:
22508387
2.

Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.

Zhong JS, Meng FY, Xu D, Zhou HS, Dai M.

Acta Haematol. 2012;127(4):221-7. doi: 10.1159/000336244. Epub 2012 Mar 30.

PMID:
22473087
3.

Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC.

Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, Rowe JM, Shimoni A, Nagler A.

Hematol Oncol. 2012 Dec;30(4):200-5. doi: 10.1002/hon.2005. Epub 2012 Jan 12.

PMID:
22241698
4.

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.

Faber E, Friedecký D, Mičová K, Rožmanová S, Divoká M, Jarošová M, Indrák K, Adam T.

Ann Hematol. 2012 Jun;91(6):923-9. doi: 10.1007/s00277-011-1394-x. Epub 2012 Jan 11.

PMID:
22231281
5.

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY.

Leuk Lymphoma. 2011 Jun;52(6):1024-9. doi: 10.3109/10428194.2011.563885. Epub 2011 Apr 4.

PMID:
21463107
6.

Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.

Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H.

Ther Drug Monit. 2011 Apr;33(2):244-50. doi: 10.1097/FTD.0b013e31820beb02.

PMID:
21311410
7.

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

Maffioli M, Camós M, Gaya A, Hernández-Boluda JC, Alvarez-Larrán A, Domingo A, Granell M, Guillem V, Vallansot R, Costa D, Bellosillo B, Colomer D, Cervantes F.

Leuk Res. 2011 Aug;35(8):1014-9. doi: 10.1016/j.leukres.2010.12.004. Epub 2010 Dec 24.

PMID:
21185600
8.

Investigation of a genome wide association signal for obesity: synthetic association and haplotype analyses at the melanocortin 4 receptor gene locus.

Scherag A, Jarick I, Grothe J, Biebermann H, Scherag S, Volckmar AL, Vogel CI, Greene B, Hebebrand J, Hinney A.

PLoS One. 2010 Nov 15;5(11):e13967. doi: 10.1371/journal.pone.0013967.

9.

Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.

Takahashi N, Wakita H, Miura M, Scott SA, Nishii K, Masuko M, Sakai M, Maeda Y, Ishige K, Kashimura M, Fujikawa K, Fukazawa M, Katayama T, Monma F, Narita M, Urase F, Furukawa T, Miyazaki Y, Katayama N, Sawada K.

Clin Pharmacol Ther. 2010 Dec;88(6):809-13. doi: 10.1038/clpt.2010.186. Epub 2010 Oct 27.

PMID:
20980997
10.

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

White DL, Saunders VA, Dang P, Engler J, Hughes TP.

Leukemia. 2010 Nov;24(11):1962-5. doi: 10.1038/leu.2010.188. Epub 2010 Sep 2. No abstract available.

PMID:
20811406
11.

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.

Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA.

Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. Review.

12.

Relationship of serum imatinib trough level and response in CML patients: long term follow-up.

Awidi A, Ayed AO, Bsoul N, Magablah A, Mefleh R, Dweiri M, Ramahi M, Arafat E, Bishtawi M, Marie L.

Leuk Res. 2010 Dec;34(12):1573-5. doi: 10.1016/j.leukres.2010.07.014. Epub 2010 Aug 4.

PMID:
20688395
13.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP; IRIS investigators..

Blood. 2010 Nov 11;116(19):3758-65. doi: 10.1182/blood-2010-03-273979. Epub 2010 Aug 2.

14.

Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.

Li QB, Chen C, Chen ZC, Wang HX, Wu YL, You Y, Zou P.

Acta Pharmacol Sin. 2010 Aug;31(8):999-1004. doi: 10.1038/aps.2010.79. Epub 2010 Jul 19.

15.

Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.

Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH, Sali A, Kubo M, Nakamura S, Iwamoto Y, Iwasaki N, Giacomini KM.

J Pharmacol Exp Ther. 2010 Oct;335(1):42-50. doi: 10.1124/jpet.110.170159. Epub 2010 Jul 16.

16.

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS.

Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6. No abstract available.

PMID:
20445576
17.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS.

J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12.

PMID:
20385986
18.

Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk.

Karami S, Brennan P, Rosenberg PS, Navratilova M, Mates D, Zaridze D, Janout V, Kollarova H, Bencko V, Matveev V, Szeszenia-Dabrowska N, Holcatova I, Yeager M, Chanock S, Menashe I, Rothman N, Chow WH, Boffetta P, Moore LE.

PLoS One. 2009 Sep 15;4(9):e7013. doi: 10.1371/journal.pone.0007013.

19.

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH.

Clin Cancer Res. 2009 Jul 15;15(14):4750-8. doi: 10.1158/1078-0432.CCR-09-0145. Epub 2009 Jul 7.

20.

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D.

J Clin Oncol. 2009 Aug 1;27(22):3642-9. doi: 10.1200/JCO.2008.19.4076. Epub 2009 Jun 8.

Supplemental Content

Support Center